Search

Author/Creator Rex, John H

1. 594. An Open-Label Study in Healthy Volunteers to Determine the Absolute Bioavailability of, the Effect of Food and Dosing by Nasogastric Tube upon the Pharmacokinetics of a Single Oral Dose of Olorofim (OLO). (15th December 2022)

Authors:
Cornelissen, Karen; Newell, Paul A; Rex, John H; Galbraith, Hal; Israel, Samuel; Bush, James; ChB, M B
Journal:
Open forum infectious diseases
Issue:
Volume 9:(2022)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 595. Olorofim (OLO) for treatment of invasive mould infections in patients with limited or no treatment options: PK data from a Phase 2b open-label study (NCT03583164, Study 32). (15th December 2022)

Authors:
Cornelissen, Karen; Wright, James G; Cristinacce, Andrew; Galbraith, Hal; Bruggemann, Roger; Maertens, Johan A; Thompson, George R; Chen, Sharon C; Rex, John H
Journal:
Open forum infectious diseases
Issue:
Volume 9:(2022)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 754. Olorofim for treatment of invasive fungal infections (IFI) due to moulds in patients with limited or no treatment options: Interim results from a Phase 2b open-label study (NCT03583164, Study 32). (15th December 2022)

Authors:
Maertens, Johan A; Thompson, George R; Spec, Andrej; Hammond, Sarah P; Rijnders, Bart; Lewis White, P; Cornely, Oliver A; Fitton, Lesley; Dane, Aaron; Rex, John H; Chen, Sharon C
Journal:
Open forum infectious diseases
Issue:
Volume 9:(2022)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 870. Olorofim for the treatment of invasive mould infections in patients with limited or no treatment options: Comparison of interim results from a Phase 2B open-label study with outcomes in historical control populations (NCT03583164, FORMULA-OLS, Study 32). (15th December 2022)

Authors:
Maertens, Johan A; Verweij, Paul E; Lanuza, Evan F; Harvey, Emma L; Dane, Aaron; Zinzi, Daniela; Rex, John H; Chen, Sharon C
Journal:
Open forum infectious diseases
Issue:
Volume 9:(2022)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Alternatives to antibiotics—a pipeline portfolio review. Issue 2 (February 2016)

Authors:
Czaplewski, Lloyd; Bax, Richard; Clokie, Martha; Dawson, Mike; Fairhead, Heather; Fischetti, Vincent A; Foster, Simon; Gilmore, Brendan F; Hancock, Robert E W; Harper, David; Henderson, Ian R; Hilpert, Kai; Jones, Brian V; Kadioglu, Aras; Knowles, David; Ólafsdóttir, Sigríður; Payne, David; Proja...
Journal:
Lancet infectious diseases
Issue:
Volume 16:Issue 2(2016:Feb.)
Page Start:
239
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Analysis of the clinical antibacterial and antituberculosis pipeline. Issue 2 (February 2019)

Authors:
Theuretzbacher, Ursula; Gottwalt, Simon; Beyer, Peter; Butler, Mark; Czaplewski, Lloyd; Lienhardt, Christian; Moja, Lorenzo; Paul, Mical; Paulin, Sarah; Rex, John H; Silver, Lynn L; Spigelman, Melvin; Thwaites, Guy E; Paccaud, Jean-Pierre; Harbarth, Stephan
Journal:
Lancet infectious diseases
Issue:
Volume 19:Issue 2(2019)
Page Start:
e40
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗